Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma

• Verfasst von: Warta, Rolf [VerfasserIn]
• Verfasst von: Theile, Dirk [VerfasserIn]
• Verfasst von: Mogler, Carolin [VerfasserIn]
• Verfasst von: Herpel, Esther [VerfasserIn]
• Verfasst von: Grabe, Niels [VerfasserIn]
• Verfasst von: Lahrmann, Bernd [VerfasserIn]
• Verfasst von: Plinkert, Peter K. [VerfasserIn]
• Verfasst von: Herold-Mende, Christel [VerfasserIn]
• Verfasst von: Weiß, Johanna [VerfasserIn]
• Verfasst von: Dyckhoff, Gerhard [VerfasserIn]
• Titel: Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma
• Verf.angabe: Rolf Warta, Dirk Theile, Carolin Mogler, Esther Herpel, Niels Grabe, Bernd Lahrmann, Peter K. Plinkert, Christel Herold-Mende, Johanna Weiss, Gerhard Dyckhoff
• E-Jahr: 2014
• Jahr: October 2, 2014
• Fussnoten: Gesehen am 14.07.2020
• Titel Quelle: Enthalten in: PLOS ONE
• Ort Quelle: San Francisco, California, US : PLOS, 2006
• Jahr Quelle: 2014
• Band/Heft Quelle: 9(2014,10) Artikel-Nummer e108908, 8 Seiten
• ISSN Quelle: 1932-6203
• DOI: doi:10.1371/journal.pone.0108908
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Antigen isotypes
• Sach-SW: Cancer chemotherapy
• Sach-SW: Gene expression
• Sach-SW: Head and neck squamous cell carcinoma
• Sach-SW: Microarrays
• Sach-SW: Protein expression
• Sach-SW: Radiation therapy
• Sach-SW: Survival analysis
• K10plus-PPN: 1724665847

Abstract

Drug transporters such as P-glycoprotein (ABCB1) have been associated with chemotherapy resistance and are considered unfavorable prognostic factors for survival of cancer patients. Analyzing mRNA expression levels of a subset of drug transporters by quantitative reverse transcription polymerase chain reaction (qRT-PCR) or protein expression by tissue microarray (TMA) in tumor samples of therapy naïve stage IV head and neck squamous cell carcinoma (HNSCC) (qRT-PCR, n = 40; TMA, n = 61), this in situ study re-examined the significance of transporter expression for progression-free survival (PFS) and overall survival (OS). Data from The Cancer Genome Atlas database was used to externally validate the respective findings (n = 317). In general, HNSCC tended to lower expression of drug transporters compared to normal epithelium. High ABCB1 mRNA tumor expression was associated with both favorable progression-free survival (PFS, p = 0.0357) and overall survival (OS, p = 0.0535). Similar results were obtained for the mRNA of ABCC1 (MRP1, multidrug resistance-associated protein 1; PFS, p = 0.0183; OS, p = 0.038). In contrast, protein expression of ATP7b (copper transporter ATP7b), mRNA expression of ABCG2 (BCRP, breast cancer resistance protein), ABCC2 (MRP2), and SLC31A1 (hCTR1, human copper transporter 1) did not correlate with survival. Cluster analysis however revealed that simultaneous high expression of SLC31A1, ABCC2, and ABCG2 indicates poor survival of HNSCC patients. In conclusion, this study militates against the intuitive dogma where high expression of drug efflux transporters indicates poor survival, but demonstrates that expression of single drug transporters might indicate even improved survival. Prospectively, combined analysis of the ‘transportome’ should rather be performed as it likely unravels meaningful data on the impact of drug transporters on survival of patients with HNSCC.